title: Evaluation of protective efficacy of an Actinobacillus pleuropneumoniae serotype 1 lipopolysaccharide-protein conjugate in mice.
abstract: Actinobacillus pleuropneumoniae is the causative agent of porcine pleuropneumonia. The major adhesin of A. pleuropneumoniae has previously been identified as a lipopolysaccharide (LPS), and more recently, we demonstrated that high molecular mass LPS were involved in A. pleuropneumoniae adherence to porcine respiratory tract cells. We postulated that immunization with a LPS-based vaccine may confer a protective immunity. The high molecular mass O-polysaccharides obtained after acid hydrolysis and chromatographic separation were conjugated to bovine serum albumin (BSA) as a protein carrier. Groups of mice were injected twice with the following antigen preparations: whole-cell preparation, outer membrane preparation, O-polysaccharide-BSA conjugate, hydrolyzed LPS and phenol/water extracted LPS. A combination of different adjuvants was also used during these immunization procedures to induce a stronger immunological response to the polysaccharide antigen. Two weeks after the second injection, the mice were challenged intranasally with either homologous A. pleuropneumoniae serotype 1 strain or a serotype 5 strain. The highest survival rate, up to 80%, compared to the control groups (P < 0.05), was recorded when the mice were injected twice with 15 micrograms of carbohydrates of O-polysaccharide-BSA conjugate mixed with the saponin-derived adjuvant Quil A. Survival rates of between 60 and 70%, twice those observed in the control groups immunized with PBS, were recorded in mice injected with the O-polysaccharide-BSA conjugate mixed with other adjuvant preparations such as alhydrogel, peanut oil and Freund's incomplete adjuvant. However, the protection induced by the conjugate antigen preparation was serotype specific, because mice challenged with a serotype 5 strain were killed. Taken together, these results confirm the important role of A. pleuropneumoniae LPS in pathogenesis.
authors.affiliation: Département de Pathologie et Microbiologie, Faculté de Médecine Vétérinaire, Université de Montréal, Québec, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Rioux
authors.forename: D
authors.initials: D
authors.lastname: Dubreuil
authors.forename: C
authors.initials: C
authors.lastname: Bégin
authors.forename: C
authors.initials: C
authors.lastname: Laferrière
authors.forename: D
authors.initials: D
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Jacques
mesh_terms: D000189:Actinobacillus Infections / Q000276:immunology* / Q000517:prevention & control*; D016977:Actinobacillus pleuropneumoniae / Q000737:chemistry* / Q000276:immunology*; D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide / Q000276:immunology; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D002462:Cell Membrane / Q000276:immunology; D004591:Electrophoresis, Polyacrylamide Gel; D004797:Enzyme-Linked Immunosorbent Assay; D005620:Freund's Adjuvant / Q000276:immunology; D015151:Immunoblotting; D008070:Lipopolysaccharides / Q000276:immunology* / Q000302:isolation & purification; D051379:Mice; D019081:O Antigens / Q000276:immunology; D010938:Plant Oils; D012710:Serum Albumin, Bovine / Q000276:immunology; D014612:Vaccines / Q000276:immunology; D018074:Vaccines, Conjugate / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D008070:Lipopolysaccharides; D019081:O Antigens; D010938:Plant Oils; D014612:Vaccines; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic; D012710:Serum Albumin, Bovine; D000536:Aluminum Hydroxide; D005620:Freund's Adjuvant